Kozak & Associates Inc. Has $111,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Kozak & Associates Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN) by 33.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 345 shares of the medical research company’s stock after purchasing an additional 87 shares during the quarter. Kozak & Associates Inc.’s holdings in Amgen were worth $111,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Meyer Handelman Co. lifted its holdings in shares of Amgen by 7.2% during the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after acquiring an additional 8,700 shares during the period. Royal Fund Management LLC boosted its holdings in Amgen by 20.1% during the first quarter. Royal Fund Management LLC now owns 17,378 shares of the medical research company’s stock valued at $4,960,000 after purchasing an additional 2,914 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Amgen by 37.4% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 11,642 shares of the medical research company’s stock valued at $3,310,000 after purchasing an additional 3,168 shares during the period. Oak Harvest Investment Services raised its holdings in shares of Amgen by 19.1% in the 1st quarter. Oak Harvest Investment Services now owns 38,067 shares of the medical research company’s stock worth $10,823,000 after buying an additional 6,116 shares in the last quarter. Finally, EP Wealth Advisors LLC lifted its position in shares of Amgen by 11.0% during the 1st quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock worth $6,758,000 after buying an additional 2,353 shares during the period. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Bank of America increased their price objective on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and increased their target price for the stock from $320.00 to $333.00 in a research report on Monday. Royal Bank of Canada restated an “outperform” rating and issued a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Barclays raised their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $329.48.

Amgen Price Performance

AMGN opened at $321.33 on Friday. The company has a fifty day moving average price of $326.08 and a two-hundred day moving average price of $311.63. The firm has a market capitalization of $172.37 billion, a PE ratio of 45.90, a P/E/G ratio of 2.86 and a beta of 0.61. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the firm earned $5.00 earnings per share. The firm’s revenue for the quarter was up 20.1% on a year-over-year basis. As a group, analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.80%. Amgen’s dividend payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.